Drug discoverers have wrestled with the problem of attrition for over a decade. Yet today, about 60% of candidate drugs still fail in clinical trials due to poor efficacy. Luckily, this old problem is finally being tackled by new solutions. Novel approaches are now...

Attrition levels in drug discovery remain high, with almost 60% of candidate drugs failing during clinical development due to insufficient efficacy. These failures have costly consequences for pharmaceutical and biotech companies. As well as gaining no return on their...

The new Alpha CETSA® HT kits available from Perkin Elmer will enable customers to utilise the power of CETSA HT in their own laboratories.  The first 5 kits will be released to coincide with SLAS Europe with further protein targets becoming available soon.  For more...

Around the world, millions of patients need new drugs for life-threatening and incurable diseases. Yet, only around 1 out of 10 candidate drugs are gaining approval to enter the market. One of the main causes of this poor rate of success is a lack of efficacy during...

On September 23, Pelago Bioscience host our very first Customer Forum in Boston, US. This forum will gather researchers from Commercial and Academic drug discovery laboratories to present and discuss recent progress in the use of CETSA. The meeting will include case...